The combination of cladribine, cytarabine, and G-CSF (CLAG) has exhibited robust synergistic anti-leukemia activity as an induction therapy (IT) in acute myeloid leukemia (AML). However, the impact of CLAG as a bridging therapy (BT) administered …
The impact of absolute neutrophil count (ANC) before allogenic hematopoietic stem cell transplantation (HSCT) on the outcomes for patients with aplastic anemia (AA) remains unclear. We retrospectively evaluated the relationship between ANC before …
Primary cardiac lymphomas (PCLs) are a rare clinical entity, in which treatment guidelines remain to be established. Rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) has been proposed, given that it …
There has been no severity evaluation model for pediatric patients with hemophagocytic lymphohistiocytosis (HLH) that uses readily available parameters. This study aimed to develop a novel model for predicting the early mortality risk in pediatric …
Tixagevimab and cilgavimab (EVA, Evusheld®), monoclonal antibody combination treatments, consisted of two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). EVA showed prophylactic and therapeutic effects …
Pembrolizumab (anti-programmed cell death-ligand 1 inhibitor) is a promising salvage therapeutic option for relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL). However, the appropriate duration of pembrolizumab use in R/R ENKTL patients …
Authors:
Sang Eun Yoon, Hyungwoo Cho, Philipp Berning, Junhun Cho, Hyun-Young Kim, Dok Hyun Yoon, Norbert Schmit, Seok Jin Kim, Won Seog Kim
Chimeric antigen receptor T (CAR-T) cells therapy is a milestone achievement in the immunotherapy of relapsed and refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL). However, some patients treated with CAR-T cells do not achieve complete …
Authors:
Ruotong Chen, Qianshan Tao, Fan Wu, Zhimin Zhai, Yuchen Jiang, Caixian Xu, Huiping Wang
Background: Acute myeloid leukemia (AML) patients with various nucleophosmin 1 (NPM1) mutations are controversial in the prognosis. This study aimed to investigate the prognosis of patients according to types of NPM1 mutations (NPM1mut). Methods: …
Authors:
Yu Shi, Xiao Chen, Huimin Jin, Liying Zhu, Ming Hong, Yu Zhu, Yujie Wu, Hairong Qiu, Yan Wang, Qian Sun, Hui Jin, Jianyong Li, Sixuan Qian, Chun Qiao
Rivaroxaban is a new direct oral anticoagulant, and the same dose is recommended for older and young patients. However, recent real-world studies show that older patients may need dose adjustment to prevent major bleeding. At present, the evidence …
Authors:
Jianwei Ren, Na Wang, Xuan Zhang, Fuyu Song, Xin Zheng, Xiaohong Han
Acute myeloid leukemia (AML) shows multiple chromosomal translocations & point mutations which can be used to refine risk-adapted therapy in AML patients. Ecotropic viral integration site-1 (EVI-1) & myocyte enhancer factor 2 C gene (MEF2C) are …
Authors:
Nadia El Menshawy, Mohamed S. El-Ghonemy, Mohamed A. Ebrahim, Maryan Waheeb Fahmi, Maha Saif, May Denewer, Shaimaa El-Ashwah
Chronic inflammation has been identified in leukemias as an essential regulator of angiogenesis. B-chronic lymphocytic leukemia (CLL) cells secrete high levels of vascular endothelial growth factor (VEGF) and hypoxia inducible factor 1 alpha …
Cardiotoxicity in children is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT); therefore, early identification of risk factors can improve patient prognosis. However, there are few data on the …
Authors:
Ke Tong, Yan Meng, Luying Zhang, Xiaoying Lei, Qihui Liu, Xianmin Guan, Jie Yu, Ying Dou
Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed/refractory aggressive large B-cell lymphoma who underwent …
Authors:
Rossana Di Staso, Beatrice Casadei, Marianna Gentilini, Serafina Guadagnuolo, Cinzia Pellegrini, Alessandro Broccoli, Davide Gori, Riccardo Masetti, Vittorio Stefoni, Francesca Bonifazi, Pier Luigi Zinzani, Lisa Argnani
Refractory/relapsed idiopathic multicentric Castleman disease (R/R iMCD) has limited treatment options. With studies showing increased mTOR activation in iMCD patients, sirolimus becomes an attractive and promising therapy for R/R iMCD. Here we …
Hematopoietic stem cells (HSCs) are an ideal source for the treatment of many hematological diseases and malignancies, as well as diseases of other systems, because of their two important features, self-renewal and multipotential differentiation …
The prognostic and predictive role of specific gene mutations in Waldenström Macroglobulinemia (WM) is well-ascertained whereas the clinical impact of chromosome aberrations is far less known. Recent work has provided initial evidence for an …
Authors:
Nicolò Danesin, Laura Bonaldi, Annalisa Martines, Silvia Nalio, Roberta Bertorelle, Sofia Compagno, Raffaella Marcato, Sabrina Manni, Federico Scarmozzino, Marco Pizzi, Angelo Paolo Dei Tos, Alessandro Cellini, Greta Scapinello, Andrea Visentin, Livio Trentin, Francesco Piazza
Differentiation syndrome (DS) is the second leading cause of death in acute promyelocytic leukaemia (APL) patients. Few studies have tested predictors of DS events. This study aimed to identify optimized predictors of DS events related to APL. The …
Authors:
Yujuan Gao, Yuanyuan Xi, Wenqi Chen, Yanfen Meng, Yanhua Su
